Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting ... - Business Wire (press release)

Submitted by Anonymous (not verified) on Mon, 11/14/2016 - 11:18

Camurus AB: Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting ...Business Wire (press release)The present Phase 3 trial was a multicenter, randomized, double blind, double dummy, active controlled study that enrolled a total of 428 patients at 36 US sites with moderate to severe opioid use disorder (DSM–5 criteria; American Psychiatric ...and more »